Supplier: ProMab Technologies
Type of Product: Monoclonal Antibody
Description: Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila). Eukaryotic RNA polymerase II mediates the synthesis of mature and functional messenger RNA. This is a multistep process, called the transcription cycle,that includes five stages: preinitiation, promoter, clearance, elongation and termination. Elongation is thought to be a critical stage for the regulation of gene expression. ELL (11-19 lysine-rich leukemia protein, also designated MEN) functions as an RNA polymerase II elongation factor that increases the rateof transcription by suppressing transient pausing by RNA polymerase II. Also, ELL is thought to regulate cellular proliferation. ELL is abundantly expressed in peripheral blood leukocytes, skeletal muscle, placenta and testis, and has lower expression in spleen, thymus, heart, brain, lung, kidney, liver and ovary.The gene encoding human ELL, which maps to chromosome 19p13.1, is one of several genes which undergo translocation with the MLL gene on chromo-some 11q23 in acute myeloid leukemia. MLL (myeloid/lymphoid leukemia,also designated ALL-1 and HRX) is a 430 kDa protein that regulates embryonal and hematopoietic development.
Application: ELISA: 1/10000; WB: 1/500 - 1/2000; IHC: 1/200 - 1/1000
Size: 100 ul, 1mg/ml
Species Reactivity: Human
Isotype: Mouse IgG1
Immunogen: Purified recombinant fragment of MLL (aa3751-3968) expressed in E. Coli.
Formulation: Ascitic fluid containing 0.03% sodium azide.
Storage: 4C; -20C for long term storage
Spplier link: http://www.promab.com/index.php?main_page=product_info&products_id=189
Reference: 1. Genet Couns. 2006;17(2):155-9. ; 2. Cancer Genet Cytogenet. 2006 Jul 15;168(2):162-7 ; 3. Leukemia. 2007 Feb;21(2):360-2. Epub 2007 Jan 4.